John D Hayes

List of Publications by Year in Descending Order

166 papers	25,826 citations	72 h-index	160 g-index
175 ext. papers	28,568 ext. citations	6.2 avg, IF	7.29 L-index

#	Paper	IF	Citations
166	Non-canonical Keap1-independent activation of Nrf2 in astrocytes by mild oxidative stress. *Redox Biology*, **2021**, 47, 102158	11.3	2
165	Oxidative Stress in Cancer. *Cancer Cell*, **2020**, 38, 167-197	24.3	402
164	NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis. *Cancers*, **2020**, 12,	6.6	20
163	Induction of the Antioxidant Response by the Transcription Factor NRF2 Increases Bioactivation of the Mutagenic Air Pollutant 3-Nitrobenzanthrone in Human Lung Cells. *Chemical Research in Toxicology*, **2019**, 32, 2538-2551	4	10
162	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. *Nature Reviews Drug Discovery*, **2019**, 18, 295-317	64.1	476
161	Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are´Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2). *Cellular and Molecular Gastroenterology and Hepatology*, **2018**, 5, 367-398	7.9	101
160	A partnership with the proteasome; the destructive nature of GSK3. *Biochemical Pharmacology*, **2018**, 147, 77-92	6	46
159	Zinc-binding triggers a conformational-switch in the cullin-3 substrate adaptor protein KEAP1 that controls transcription factor NRF2. *Toxicology and Applied Pharmacology*, **2018**, 360, 45-57	4.6	14
158	Characterization of liver injury, oval cell proliferation and cholangiocarcinogenesis in glutathione S-transferase A3 knockout mice. *Carcinogenesis*, **2017**, 38, 717-727	4.6	15
157	Exploring nonlinear pulse propagation, Raman frequency conversion and near octave spanning supercontinuum generation in atmospheric air-filled hollow-core Kagom Fiber **2017**,		2
156	Con Drury: philosopher and psychiatrist. *History of Psychiatry*, **2017**, 28, 391-409	0.6	1
155	Oncogene-Stimulated Congestion at the KEAP1 Stress Signaling Hub Allows Bypass of NRF2 and Induction of NRF2-Target Genes that Promote Tumor Survival. *Cancer Cell*, **2017**, 32, 539-541	24.3	14
154	Low signal correction scheme for low dose CBCT: the good, the bad, and the ugly **2017**,		3
153	A leptin-regulated circuit controls glucose mobilization during noxious stimuli. *Journal of Clinical Investigation*, **2017**, 127, 3103-3113	15.9	21
152	Beam-Steering All-Optical Switch for Multi-Core Fibers **2017**,		13
151	Epigenetic Control of NRF2-Directed Cellular Antioxidant Status in Dictating Life-Death Decisions. *Molecular Cell*, **2017**, 68, 5-7	17.6	14
150	Nrf2-Mediated Neuroprotection Against Recurrent Hypoglycemia Is Insufficient to Prevent Cognitive Impairment in a Rodent Model of Type 1 Diabetes. *Diabetes*, **2016**, 65, 3151-60	0.9	24

149	Regulation of the CNC-bZIP transcription factor Nrf2 by Keap1 and the axis between GSK-3 and □TrCP. *Current Opinion in Toxicology*, **2016**, 1, 92-103	4.4	12
148	Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. *Free Radical Biology and Medicine*, **2015**, 88, 108-146	7.8	483
147	Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2. *Nature Communications*, **2015**, 6, 7066	17.4	101
146	Dual regulation of transcription factor Nrf2 by Keap1 and by the combined actions of □TrCP and GSK-3. *Biochemical Society Transactions*, **2015**, 43, 611-20	5.1	104
145	The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic. *Biochemical Society Transactions*, **2015**, 43, 687-9	5.1	118
144	The selective post-translational processing of transcription factor Nrf1 yields distinct isoforms that dictate its ability to differentially regulate gene expression. *Scientific Reports*, **2015**, 5, 12983	4.9	32
143	Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants. *Haematologica*, **2015**, 100, 1076-85	6.6	10
142	The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. *Trends in Biochemical Sciences*, **2014**, 39, 199-218	10.3	1157
141	3-(2-oxoethylidene)indolin-2-one derivatives activate Nrf2 and inhibit NF-□B: potential candidates for chemoprevention. *ChemMedChem*, **2014**, 9, 1763-74	3.7	3
140	Nrf2 target genes can be controlled by neuronal activity in the absence of Nrf2 and astrocytes. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E1818-20	11.5	20
139	Transcription factor Nrf1 is topologically repartitioned across membranes to enable target gene transactivation through its acidic glucose-responsive domains. *PLoS ONE*, **2014**, 9, e93458	3.7	31
138	Transcription factor Nrf1 negatively regulates the cystine/glutamate transporter and lipid-metabolizing enzymes. *Molecular and Cellular Biology*, **2014**, 34, 3800-16	4.8	46
137	Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. *Molecular and Cellular Biology*, **2014**, 34, 3305-20	4.8	141
136	Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2□and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy. *Antioxidants and Redox Signaling*, **2014**, 20, 2907-22	8.4	48
135	A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF-□B and Nrf2-Keap1 signaling pathways. *Toxicology and Applied Pharmacology*, **2013**, 272, 852-62	4.6	34
134	The gasotransmitter hydrogen sulfide induces nrf2-target genes by inactivating the keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys-226 and cys-613. *Antioxidants and Redox Signaling*, **2013**, 19, 465-81	8.4	143
133	The membrane-topogenic vectorial behaviour of Nrf1 controls its post-translational modification and transactivation activity. *Scientific Reports*, **2013**, 3, 2006	4.9	27
132	Nrf2 is controlled by two distinct □TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. *Oncogene*, **2013**, 32, 3765-81	9.2	388

131	RXR□nhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. *Cancer Research*, **2013**, 73, 3097-108	10.1	195
130	Nrf2 orchestrates fuel partitioning for cell proliferation. *Cell Metabolism*, **2012**, 16, 139-41	24.6	38
129	Analysis of the role of Nrf2 in the expression of liver proteins in mice using two-dimensional gel-based proteomics. *Pharmacological Reports*, **2012**, 64, 680-97	3.9	30
128	Peptide inhibitors of the Keap1-Nrf2 protein-protein interaction. *Free Radical Biology and Medicine*, **2012**, 52, 444-51	7.8	102
127	Human embryonic stem cell derived astrocytes mediate non-cell-autonomous neuroprotection through endogenous and drug-induced mechanisms. *Cell Death and Differentiation*, **2012**, 19, 779-87	12.7	66
126	Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/□TrCP axis. *Molecular and Cellular Biology*, **2012**, 32, 3486-99	4.8	217
125	Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents. *Drug Metabolism Reviews*, **2011**, 43, 92-137	7	156
124	The cap'n'collar transcription factor Nrf2 mediates both intrinsic resistance to environmental stressors and an adaptive response elicited by chemopreventive agents that determines susceptibility to electrophilic xenobiotics. *Chemico-Biological Interactions*, **2011**, 192, 37-45	5	38
123	SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. *Molecular and Cellular Biology*, **2011**, 31, 1121-33	4.8	493
122	Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, E1-2; author reply E3-4	11.5	112
121	Expression and localization of rat aldo-keto reductases and induction of the 1B13 and 1D2 isoforms by phenolic antioxidants. *Drug Metabolism and Disposition*, **2010**, 38, 341-6	4	6
120	Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 18838-43	11.5	309
119	Peroxiredoxin gene expression signatures in liver reflect toxic insult. *Assay and Drug Development Technologies*, **2010**, 8, 512-7	2.1	6
118	p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. *Journal of Biological Chemistry*, **2010**, 285, 22576-91	5.4	928
117	Nrf2, a guardian of healthspan and gatekeeper of species longevity. *Integrative and Comparative Biology*, **2010**, 50, 829-43	2.8	173
116	Identification of topological determinants in the N-terminal domain of transcription factor Nrf1 that control its orientation in the endoplasmic reticulum membrane. *Biochemical Journal*, **2010**, 430, 497-510	3.8	34
115	Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. *Antioxidants and Redox Signaling*, **2010**, 13, 1713-48	8.4	413
114	Spatial monitoring of toxicity in HMOX-LacZ transgenic mice. *Transgenic Research*, **2010**, 19, 897-902	3.3	7

113	Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. *Free Radical Biology and Medicine*, **2010**, 48, 357-71	7.8	190
112	Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. *Journal of Proteomics*, **2010**, 73, 1612-31	3.9	118
111	Activation of the NRF2 signaling pathway by copper-mediated redox cycling of para- and ortho-hydroquinones. *Chemistry and Biology*, **2010**, 17, 75-85		84
110	Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase. *European Journal of Medicinal Chemistry*, **2010**, 45, 447-54	6.8	14
109	The Nrf3 transcription factor is a membrane-bound glycoprotein targeted to the endoplasmic reticulum through its N-terminal homology box 1 sequence. *Journal of Biological Chemistry*, **2009**, 284, 3195-3210	5.4	55
108	Cross-talk between transcription factors AhR and Nrf2: lessons for cancer chemoprevention from dioxin. *Toxicological Sciences*, **2009**, 111, 199-201	4.4	76
107	1-Cyano-2,3-epithiopropane is a novel plant-derived chemopreventive agent which induces cytoprotective genes that afford resistance against the genotoxic alpha,beta-unsaturated aldehyde acrolein. *Carcinogenesis*, **2009**, 30, 1754-62	4.6	34
106	Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. *Carcinogenesis*,	4.6	240
105	Transcription factor Nrf2 mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic effects of electrophiles, peroxides and redox-cycling agents. *Toxicology and Applied Pharmacology*, **2009**, 237, 267-80	4.6	135
104	NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. *Trends in Biochemical Sciences*, **2009**, 34, 176-88	10.3	671
103	The Nrf1 CNC/bZIP protein is a nuclear envelope-bound transcription factor that is activated by t-butyl hydroquinone but not by endoplasmic reticulum stressors. *Biochemical Journal*, **2009**, 418, 293-310	3.8	54
102	Induction of sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the neuroprotective Nrf2 activator 3H-1,2-dithiole-3-thione. *Journal of Neurochemistry*, **2008**, 107, 533-43	6	100
101	Induction of cancer chemopreventive enzymes by coffee is mediated by transcription factor Nrf2. Evidence that the coffee-specific diterpenes cafestol and kahweol confer protection against acrolein. *Toxicology and Applied Pharmacology*, **2008**, 226, 328-37	4.6	99
100	Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. *Journal of Biological Chemistry*, **2008**, 283, 33554-62	5.4	230
99	The cancer chemopreventive actions of phytochemicals derived from glucosinolates. *European Journal of Nutrition*, **2008**, 47 Suppl 2, 73-88	5.2	298
98	The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. *Hepatology*, **2008**, 48, 1292-301	11.2	98
97	Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 19589-94	11.5	216
96	The NHB1 (N-terminal homology box 1) sequence in transcription factor Nrf1 is required to anchor it to the endoplasmic reticulum and also to enable its asparagine-glycosylation. *Biochemical Journal* , **2007**, 408, 161-72	3.8	71

95	Using participant event monitoring in a cohort study of unintentional injuries among children and adolescents. *American Journal of Public Health*, **2007**, 97, 283-90	5.1	8
94	Reduction in antioxidant defenses may contribute to ochratoxin A toxicity and carcinogenicity. *Toxicological Sciences*, **2007**, 96, 30-9	4.4	111
93	Dimerisation of adaptor protein Keap1 is required to correctly position Nrf2 for ubiquitylation upon the Cul3-Rbx1 holoenzyme: the fixed-ends model. *FASEB Journal*, **2007**, 21, A1020	0.9	
92	Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. *Journal of Biological Chemistry*, **2006**, 281, 24756-68	5.4	364
91	Deficiency of glutathione transferase zeta causes oxidative stress and activation of antioxidant response pathways. *Molecular Pharmacology*, **2006**, 69, 650-7	4.3	64
90	Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. *Cancer Research*, **2006**, 66, 10983-94	10.1	227
89	The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. *Molecular Cell*, **2006**, 21, 732-4	17.6	107
88	Negative regulation of the Nrf1 transcription factor by its N-terminal domain is independent of Keap1: Nrf1, but not Nrf2, is targeted to the endoplasmic reticulum. *Biochemical Journal*, **2006**, 399, 373-85	3.8	96
87	Hyperglycemia is a marker for poor outcome in the postoperative pediatric cardiac patient. *Pediatric Critical Care Medicine*, **2006**, 7, 351-5	3	139
86	Mammalian Glutathione S-Transferase Genes **2006**, 27-46		
85	Nomenclature for mammalian soluble glutathione transferases. *Methods in Enzymology*, **2005**, 401, 1-8	1.7	236
84	Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. *Archives of Biochemistry and Biophysics*, **2005**, 433, 342-50	4.1	169
83	Glutathione transferases. *Annual Review of Pharmacology and Toxicology*, **2005**, 45, 51-88	17.9	2724
82	Utility of siRNA against Keap1 as a strategy to stimulate a cancer chemopreventive phenotype. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 7280-7285A	11.5	107
81	Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. *Journal of Nutrition*, **2004**, 134, 3499S-3506S	4.1	167
80	Tissue-specific expression and subcellular distribution of murine glutathione S-transferase class kappa. *Journal of Histochemistry and Cytochemistry*, **2004**, 52, 653-62	3.4	40
79	Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. *Journal of Biological Chemistry*, **2004**, 279, 31556-67	5.4	276
78	Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2004**, 555, 149-71	3.3	279

77	Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. *Hepatology*, **2004**, 39, 1267-76	11.2	166
76	Antioxidant and cytoprotective responses to redox stress. *Biochemical Society Symposia*, **2004**, 157-76		84
75	Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. *Journal of Biological Chemistry*, **2003**, 278, 21592-600	5.4	806
74	Characterization of the rat aflatoxin B1 aldehyde reductase gene, AKR7A1. Structure and chromosomal localization of AKR7A1 as well as identification of antioxidant response elements in the gene promoter. *Carcinogenesis*, **2003**, 24, 727-37	4.6	28
73	Alteration of glutathione S-transferase levels in Barrett's metaplasia compared to normal oesophageal epithelium. *European Journal of Gastroenterology and Hepatology*, **2003**, 15, 41-7	2.2	11
72	Biochemical and genetic characterization of a murine class Kappa glutathione S-transferase. *Biochemical Journal*, **2003**, 373, 559-69	3.8	56
71	Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. *Biochemical Journal*, **2003**, 374, 337-48	3.8	375
70	Competing Reactions of Aflatoxin B1 Dialdehyde: Enzymatic Reduction versus Adduction with Lysine. *ACS Symposium Series*, **2003**, 171-182	0.4	1
69	Aflatoxin Aldehyde Reductases. *ACS Symposium Series*, **2003**, 155-170	0.4	3
68	Positive and negative regulation of prostaglandin E2 biosynthesis in human colorectal carcinoma cells by cancer chemopreventive agents. *Biochemical Pharmacology*, **2003**, 66, 51-61	6	23
67	Prostaglandin D2 synthase enzymes and PPARgamma are co-expressed in mouse 3T3-L1 adipocytes and human tissues. *Prostaglandins and Other Lipid Mediators*, **2003**, 70, 267-84	3.7	40
66	Expression of the murine glutathione S-transferase alpha3 (GSTA3) subunit is markedly induced during adipocyte differentiation: activation of the GSTA3 gene promoter by the pro-adipogenic eicosanoid 15-deoxy-Delta12,14-prostaglandin J2. *Biochemical and Biophysical Research Communications*, **2003**, 312, 1226-35	3.4	35
65	Expression of the aflatoxin B1-8,9-epoxide-metabolizing murine glutathione S-transferase A3 subunit is regulated by the Nrf2 transcription factor through an antioxidant response element. *Molecular Pharmacology*, **2003**, 64, 1018-28	4.3	59
64	Direct comparison of the nature of mouse and human GST T1-1 and the implications on dichloromethane carcinogenicity. *Toxicology and Applied Pharmacology*, **2002**, 179, 89-97	4.6	37
63	Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. *Biochemical Journal*, **2002**, 365, 405-16	3.8	350
62	Novel homodimeric and heterodimeric rat gamma-hydroxybutyrate synthases that associate with the Golgi apparatus define a distinct subclass of aldo-keto reductase 7 family proteins. *Biochemical Journal*, **2002**, 366, 847-61	3.8	35
61	Glutathione S-transferases **2002**, 319-352		41
60	Mammalian class Sigma glutathione S-transferases: catalytic properties and tissue-specific expression of human and rat GSH-dependent prostaglandin D2 synthases. *Biochemical Journal*, **2001**, 359, 507-516	3.8	85

59	Mammalian class Sigma glutathione S-transferases: catalytic properties and tissue-specific expression of human and rat GSH-dependent prostaglandin D2 synthases. *Biochemical Journal*, **2001**, 359, 507-16	3.8	55
58	Expression of rat aldehyde reductase AKR7A1: influence of age and sex and tissue-specific inducibility. *Biochemical Pharmacology*, **2001**, 62, 1511-9	6	8
57	Elevation of AKR7A2 (succinic semialdehyde reductase) in neurodegenerative disease. *Brain Research*, **2001**, 916, 229-38	3.7	50
56	Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention. *Cancer Letters*, **2001**, 174, 103-13	9.9	288
55	Reduction of aflatoxin B1 dialdehyde by rat and human aldo-keto reductases. *Chemical Research in Toxicology*, **2001**, 14, 727-37	4	58
54	Purification from rat liver of a novel constitutively expressed member of the aldo-keto reductase 7 family that is widely distributed in extrahepatic tissues. *Biochemical Journal*, **2000**, 348, 389	3.8	10
53	Purification from rat liver of a novel constitutively expressed member of the aldo-keto reductase 7 family that is widely distributed in extrahepatic tissues. *Biochemical Journal*, **2000**, 348, 389-400	3.8	34
52	Glutathione S-transferase polymorphisms and their biological consequences. *Pharmacology*, **2000**, 61, 154-66	2.3	768
51	11. Cellular response to cancer chemopreventive agents: contribution of the antioxidant responsive element to the adaptive response to oxidative and chemical stress **1999**, 141-168		14
50	Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. *Free Radical Research*, **1999**, 31, 273-300	4	1109
49	Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. *Biochemical Journal*, **1999**, 343, 487	3.8	84
48	Determinants of specificity for aflatoxin B1-8,9-epoxide in Alpha-class glutathione S-transferases. *Biochemical Journal*, **1999**, 339, 95-101	3.8	11
47	Determinants of specificity for aflatoxin B1-8,9-epoxide in Alpha-class glutathione S-transferases. *Biochemical Journal*, **1999**, 339, 95	3.8	2
46	Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. *Biochemical Journal*, **1999**, 343, 487-504	3.8	172
45	Regulation of rat glutathione S-transferase A5 by cancer chemopreventive agents: mechanisms of inducible resistance to aflatoxin B1. *Chemico-Biological Interactions*, **1998**, 111-112, 51-67	5	72
44	Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo-keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B1-aldehyde reductase. *Biochemical Journal*, **1998**, 332 (Pt 1), 21-34	3.8	78
43	Sequence, catalytic properties and expression of chicken glutathione-dependent prostaglandin D2 synthase, a novel class Sigma glutathione S-transferase. *Biochemical Journal*, **1998**, 333 (Pt 2), 317-25	3.8	71
42	Growth hormone- and testosterone-dependent regulation of glutathione transferase subunit A5 in rat liver. *Biochemical Journal*, **1998**, 332 (Pt 3), 763-8	3.8	22

41	Increased bioactivation of dihaloalkanes in rat liver due to induction of class theta glutathione S-transferase T1-1. *Biochemical Journal*, **1998**, 335 (Pt 3), 619-30	3.8	72
40	Evidence that human class Theta glutathione S-transferase T1-1 can catalyse the activation of dichloromethane, a liver and lung carcinogen in the mouse. Comparison of the tissue distribution of GST T1-1 with that of classes Alpha, Mu and Pi GST in human. *Biochemical Journal*, **1997**, 326 (Pt 3), 837-46	3.8	128
39	Conjugation of highly reactive aflatoxin B1 exo-8,9-epoxide catalyzed by rat and human glutathione transferases: estimation of kinetic parameters. *Biochemistry*, **1997**, 36, 3056-60	3.2	72
38	Characterization of the rat glutathione S-transferase Yc2 subunit gene, GSTA5: identification of a putative antioxidant-responsive element in the 5'-flanking region of rat GSTA5 that may mediate chemoprotection against aflatoxin B1. *Biochemical Journal*, **1996**, 318 (Pt 1), 75-84	3.8	39
37	Allelism at the glutathione S-transferase GSTM3 locus: interactions with GSTM1 and GSTT1 as risk factors for astrocytoma. *Carcinogenesis*, **1996**, 17, 1919-22	4.6	49
36	Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz. *Toxicology and Applied Pharmacology*, **1995**, 135, 45-57	4.6	167
35	Cut-price knockout?. *Human and Experimental Toxicology*, **1995**, 14, 929-30	3.4	
34	Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. *Carcinogenesis*, **1995**, 16, 707-11	4.6	158
33	Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. *Free Radical Research*, **1995**, 22, 193-207	4	294
32	The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. *Critical Reviews in Biochemistry and Molecular Biology*, **1995**, 30, 445-600	8.7	2578
31	The Glut athione S-Transferase Supergene Family: Regulation of GST and the Contribution of the lsoenzymes to Cancer Chemoprotection and Drug Resistance Part II. *Critical Reviews in Biochemistry and Molecular Biology*, **1995**, 30, 521-600	8.7	97
30	Localisation of alpha, mu and pi class glutathione S-transferases in kidney: comparison with CuZn superoxide dismutase. *Biochimica Et Biophysica Acta - General Subjects*, **1993**, 1157, 204-8	4	14
29	Glutathione S-transferases: biomedical applications. *Advances in Clinical Chemistry*, **1993**, 30, 281-380	5.8	179
28	Increased levels of alpha-class and pi-class glutathione S-transferases in cell lines resistant to 1-chloro-2,4-dinitrobenzene. *FEBS Journal*, **1993**, 217, 671-6		19
27	Human Mu-class glutathione S-transferases present in liver, skeletal muscle and testicular tissue. *BBA - Proteins and Proteomics*, **1993**, 1203, 131-41		29
26	Modulation of glutathione S-transferases and glutathione peroxidase by the anticarcinogen butylated hydroxyanisole in murine extrahepatic organs. *Carcinogenesis*, **1992**, 13, 2255-61	4.6	20
25	Over-expression of P-glycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistance in vitro. *International Journal of Cancer*, **1992**, 52, 241-6	7.5	41
24	The major glutathione S-transferase in salmonid fish livers is homologous to the mammalian pi-class GST. *Comparative Biochemistry and Physiology Part B: Comparative Biochemistry*, **1991**, 100, 93-8		33

23	Enhanced expression of glutathione S-transferases in colorectal carcinoma compared to non-neoplastic mucosa. *Carcinogenesis*, **1991**, 12, 13-7	4.6	50
22	Contribution of the glutathione S-transferases to the mechanisms of resistance to aflatoxin B1 **1991**, 50, 443-72		91
21	Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. *Carcinogenesis*, **1991**, 12, 1533-7	4.6	225
20	Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data. *British Journal of Cancer*, **1990**, 62, 209-12	8.7	36
19	Glutathione S-transferase localization in aflatoxin B1-treated rat livers. *Carcinogenesis*, **1990**, 11, 927-31	4.6	14
18	Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. *Carcinogenesis*, **1990**, 11, 2163-70	4.6	76
17	Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues. *Carcinogenesis*, **1990**, 11, 451-8	4.6	219
16	Glutathione S-transferase isoenzymes in human renal carcinoma demonstrated by immunohistochemistry. *Carcinogenesis*, **1989**, 10, 1257-60	4.6	38
15	Expression of glyoxalase, glutathione peroxidase and glutathione S-transferase isoenzymes in different bovine tissues. *BBA - Proteins and Proteomics*, **1989**, 994, 21-9		21
14	Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines. *British Journal of Cancer*, **1989**, 60, 327-31	8.7	58
13	Fish and mammalian liver cytosolic glutathione S-transferases: Substrate specificities and immunological comparison. *Marine Environmental Research*, **1989**, 28, 41-46	3.3	25
12	Purification of acidic glutathione S-transferases from human lung, placenta and erythrocyte and the development of a specific radioimmunoassay for their measurement. *Clinica Chimica Acta*, **1988** , 177, 65-75	6.2	24
11	Glutathione S-transferase levels in autoimmune chronic active hepatitis: a more sensitive index of hepatocellular damage than aspartate transaminase. *Clinica Chimica Acta*, **1988**, 172, 211-6	6.2	25
10	Decreased hepatic glutathione S-transferase A, AA and L concentration produced by prolonged thyroid hormone administration. *Biochemical Pharmacology*, **1988**, 37, 3201-4	6	14
9	Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects. *Carcinogenesis*, **1988**, 9, 1283-7	4.6	186
8	Glutathione S-transferase isoenzymes and glutathione peroxidase activity in normal and tumour samples from human lung. *Carcinogenesis*, **1988**, 9, 1617-21	4.6	70
7	Glutathione S-transferases in man: the relationship between rat and human enzymes. *Biochemical Society Transactions*, **1987**, 15, 721-5	5.1	30
6	The polymorphic expression of neutral glutathione S-transferase in human mononuclear leucocytes as measured by specific radioimmunoassay. *Biochemical Pharmacology*, **1987**, 36, 4013-5	6	47

5	Plasma glutathione S-transferase measurements in patients with alcoholic cirrhosis. *Clinica Chimica Acta*, **1987**, 169, 85-9	6.2	14
4	Plasma Glutathione S-Transferase Measurements and Liver Disease in Man. *Journal of Clinical Biochemistry and Nutrition*, **1987**, 2, 1-24	3.1	41
3	Variations in the glutathione S-transferase subunits expressed in human livers. *BBA - Proteins and Proteomics*, **1986**, 874, 1-12		51
2	Purification of bile acid-binding proteins from rat hepatic cytosol. Use of a photoaffinity label to detect novel Y' binders. *Lipids and Lipid Metabolism*, **1986**, 875, 270-85		8
1	Plasma glutathione S-transferase measurements by radioimmunoassay: a sensitive index of hepatocellular damage in man. *Clinica Chimica Acta*, **1985**, 146, 11-9	6.2	23